Former FDA Commissioner Says Acting Head Can Stabilize Agency
Former FDA commissioner David Kessler said acting commissioner Kyle Diamantas has the background to bring stability to the agency during a period of leadership changes. Kessler spoke at the STAT Breakthrough Summit West in San Francisco on Tuesday.
prnewswire.comFormer FDA commissioner David Kessler said the agency’s acting commissioner can provide stability after recent leadership turnover. Kessler spoke at STAT’s Breakthrough Summit West in San Francisco on Tuesday. He said Kyle Diamantas understands agency processes despite not being a physician.
Administration has seen several high-profile departures in recent months. Kessler described the current period as an opportunity for the agency to improve operations. Diamantas, an attorney, was appointed acting commissioner following those exits. Kessler told the audience he has “great confidence” in Diamantas.
Kessler served as FDA commissioner from 1990 to 1997. He said Diamantas can serve as a stabilizing force for staff and regulatory work.
Key Facts
Story Timeline
2 events- May 19, 2026
Former FDA commissioner David Kessler spoke at STAT Breakthrough Summit West in San Francisco.
1 source@statnews - Recent months
FDA experienced several high-profile leadership exits.
1 source@statnews
Potential Impact
- 01
Agency staff may experience more consistent leadership during the transition period.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…